These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30920339)

  • 21. LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization.
    Verma MK; Goel RN; Bokare AM; Dandekar MP; Koul S; Desai S; Tota S; Singh N; Nigade PB; Patil VB; Modi D; Mehta M; Gundu J; Walunj SS; Karche NP; Sinha N; Kamboj RK; Palle VP
    Eur J Pharmacol; 2021 Jan; 891():173685. PubMed ID: 33127363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.
    Stevens KE; Zheng L; Floyd KL; Stitzel JA
    Brain Res; 2015 Jun; 1611():8-17. PubMed ID: 25744161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk.
    Ross RG; Hunter SK; McCarthy L; Beuler J; Hutchison AK; Wagner BD; Leonard S; Stevens KE; Freedman R
    Am J Psychiatry; 2013 Mar; 170(3):290-8. PubMed ID: 23318559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
    Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
    J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
    Nikiforuk A; Potasiewicz A; Kos T; Popik P
    Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects.
    Hahn B; Shrieves ME; Olmstead CK; Yuille MB; Chiappelli JJ; Pereira EFR; Albuquerque EX; Fawcett WP
    Psychopharmacology (Berl); 2020 Jan; 237(1):219-230. PubMed ID: 31686175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Biological Evaluation of Novel Triazine Derivatives as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors.
    Wang X; Xiao H; Wang J; Huang Z; Peng G; Xie W; Bian X; Liu H; Shi C; Yang T; Li X; Gao J; Meng Y; Jiang Q; Chen W; Hu F; Wei N; Wang X; Zhang L; Wang K; Sun Q
    J Med Chem; 2021 Aug; 64(16):12379-12396. PubMed ID: 34374537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia.
    Hajós M; Rogers BN
    Curr Pharm Des; 2010; 16(5):538-54. PubMed ID: 19909231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.
    Gee KW; Olincy A; Kanner R; Johnson L; Hogenkamp D; Harris J; Tran M; Edmonds SA; Sauer W; Yoshimura R; Johnstone T; Freedman R
    J Psychopharmacol; 2017 Apr; 31(4):434-441. PubMed ID: 28196430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
    Pieschl RL; Miller R; Jones KM; Post-Munson DJ; Chen P; Newberry K; Benitex Y; Molski T; Morgan D; McDonald IM; Macor JE; Olson RE; Asaka Y; Digavalli S; Easton A; Herrington J; Westphal RS; Lodge NJ; Zaczek R; Bristow LJ; Li YW
    Eur J Pharmacol; 2017 Jul; 807():1-11. PubMed ID: 28438647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism.
    Uslu G; Savci V; Buyukuysal LR; Goktalay G
    Neurosci Lett; 2014 May; 569():153-7. PubMed ID: 24708927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
    Hajós M; Hurst RS; Hoffmann WE; Krause M; Wall TM; Higdon NR; Groppi VE
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1213-22. PubMed ID: 15523001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
    Faghih R; Gfesser GA; Gopalakrishnan M
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers.
    Knott V; Salle S; Smith D; Choueiry J; Impey D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
    Neurosci Lett; 2015 Mar; 591():121-125. PubMed ID: 25700947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.
    de la Salle S; Smith D; Choueiry J; Impey D; Philippe T; Dort H; Millar A; Albert P; Knott V
    Neuroscience; 2013 Jun; 241():147-56. PubMed ID: 23535252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
    Freedman R
    Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.
    Xia L; Liu L; Hong X; Wang D; Wei G; Wang J; Zhou H; Xu H; Tian Y; Dai Q; Wu HE; Chang C; Wang L; Kosten TR; Zhang XY
    Neuropsychopharmacology; 2020 Jul; 45(8):1362-1368. PubMed ID: 32349117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.